Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerard B Fox

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
The Journal of Pharmacology and Experimental Therapeutics|July 21, 2012
Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonistTimothy A Esbenshade, Kaitlin E Browman, Thomas R Miller, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 22, 2008
Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imagingBetty B Yao, Gin Hsieh, Anthony V Daza, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 21, 2004
Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonistGerard B Fox, Timothy A Esbenshade, Jia Bao Pan, et al.
Biochemical Pharmacology|March 21, 2007
Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activityMarlon Cowart, Gregory A Gfesser, Kaitlin E Browman, et al.
Epilepsia|September 9, 2005
Preclinical profiling and safety studies of ABT-769: a compound with potential for broad-spectrum antiepileptic activityWilliam J Giardina, Michael J Dart, Richard R Harris, et al.
CNS Neuroscience & Therapeutics|May 17, 2008
Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing propertiesKarin R Tietje, David J Anderson, R Scott Bitner, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
The Journal of Pharmacology and Experimental Therapeutics|July 21, 2012
Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonistTimothy A Esbenshade, Kaitlin E Browman, Thomas R Miller, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 22, 2008
Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imagingBetty B Yao, Gin Hsieh, Anthony V Daza, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 21, 2004
Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonistGerard B Fox, Timothy A Esbenshade, Jia Bao Pan, et al.
Biochemical Pharmacology|March 21, 2007
Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activityMarlon Cowart, Gregory A Gfesser, Kaitlin E Browman, et al.
Epilepsia|September 9, 2005
Preclinical profiling and safety studies of ABT-769: a compound with potential for broad-spectrum antiepileptic activityWilliam J Giardina, Michael J Dart, Richard R Harris, et al.
CNS Neuroscience & Therapeutics|May 17, 2008
Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing propertiesKarin R Tietje, David J Anderson, R Scott Bitner, et al.
Pageof 7